Is This the Anti-Aging Pill We’ve All Been Waiting For?
MIT Technology Review - 28-Mar-2017Low-dose everolimus may boost flu response in elderly by rejuvenating immune function
Join the club for FREE to access the whole archive and other member benefits.
Biotherapeutics co developing new medicines for devastating diseases
PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including intractable cancers, lymphatic and gastrointestinal diseases, central nervous system disorders and inflammatory and immunological diseases, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech’s Founded Entities, is comprised of 24 products and product candidates, including two that have been cleared by the U.S. Food and Drug Administration (FDA). All of the underlying programs and platforms that resulted in this pipeline of product candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on the Company’s unique insights into the biology of the brain, immune and gut, or BIG, systems and the interface between those systems, referred to as the BIG Axis.
Visit website: https://puretechhealth.com/
Details last updated 05-Nov-2020
Low-dose everolimus may boost flu response in elderly by rejuvenating immune function